Galimedix Therapeutics, Inc.’s Post

Immunopeptidomics plays a crucial role in advancing innovative therapies targeting HLA-presented peptides. Are we ready to integrate Immunopeptidomics into clinical practice? Join the webinar featuring Tim Fugmann from Alithea Bio as he explores into immunopeptidomes with the timsTOF Ultra. Discover how leveraging extensive HLA databases can accelerate the drug development process significantly. #iPEP #timsTOF #StayCurious Shourjo Ghose Ph.D. Torsten Müller Dijana Vitko Link to webinar: https://lnkd.in/gz662mvE

📣 Webinar Alert : Immunopeptidomics 📅 29th October 2024, 4:00 - 5:00 pm CET Register now and listen to Tim Fugmann, Ph.D., CSO and Co-Founder of Alithea Biotechnology which supports Biopharma on the development of innovative therapies targeting HLA-presented peptides. Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery. Join and and discover how the timsTOF Ultra can lead to high quality immunopeptidomes from limited sample! #immunopeptidomics #immunepeptide #HLA #timsTOF #massspectrometry #Bruker

Stay tuned and join the webinar with our Chief Scientific Officer, Dr. Tim Fugamnn to get deep insights into #immunopeptidomics with Bruker Corporation and Alithea Bio.

InMed's INM-901 is a novel, small molecule drug candidate in development for the treatment of #Alzheimer's disease. Preclinical studies of INM-901 demonstrate neuroprotective effects, reduced #neuroinflammation, an ability to promote the growth of neurites and improvement in behavior, cognitive function and memory. INM-901 may target several biological pathways associated with #AlzheimersDisease with studies indicating it targets CB1, CB2 and PPAR pathways. CEO Eric A. Adams presents InMed's INM-901 program in this video: https://ow.ly/41Ab50SWjN9 $INM

Can ctDNA predict outcomes in early phase trials?  Two studies presented at #ESMOTAT24 suggest that circulating tumour (ct)DNA could be a useful tumour-agnostic biomarker that may expedite the assessment of new therapeutics.  In an #ESMODailyReporter article, Christian Rolfo, MD, PhD, MBA,Dr.h.c. comments that ctDNA analysis is non-invasive, rapid and relatively inexpensive, and results from studies further open up its potential to be more widely applied in early phase #ClinicalTrials. 👉Read the full article here https://ow.ly/eTfU50QIha5

Meet our latest addition to Ncardia’s cell portfolio! Introducing Ncyte® aCardiomyocytes, our newest cell model for cardiovascular research and toxicity studies! Improve in vitro testing of new treatments for atrial arrhythmias or cardiotoxicity assessments with this cell model: 🔶 High purity and chamber specific 🔶 Based on human biology 🔶 Suitable for drug screening Ncyte® aCardiomyocytes can be applied throughout the entire drug discovery pipeline, from extensive screening to crucial decision-making stages in hit-to-lead and lead optimization processes. Learn more here: https://lnkd.in/dyZz_TwZ #stemcell #atrial #cardiacdisease #cardiotoxicity #humanbiology #Ncardia #CardiovascularResearch

Resmetirom (Rezdiffra®) is the first FDA-approved drug for the management of MASH. At Gubra, we have established highly robust and reproducible therapeutic outcomes of Resmetirom intervention treatment in the translational, biopsy-confirmed GAN DIO-MASH mouse model. The GAN DIO-MASH mouse is Gubra's flagship model readily applicable for efficacy profiling of preclinical drug candidates. Download the poster and learn more about Resmetirom's effects on clinically relevant metabolic, biochemical and histological endpoints in the model. #MASH #NASH #TranslationalModel #ClinicalTranslatability #Resmetirom #Rezdiffra

AM-411 is Altamira Therapeutics' groundbreaking candidate for the treatment of #rheumatoidarthritis. An intraveneously administered nanoparticle based on the OligoPhore™ platform, AM-411 targets p65, one of the main transcriptional regulators of the NF-kB pathway and a key checkpoint in #RA inflammation What are the key differentiating factors of AM-411? - Reduced systemic side effects: Mediators of inflammation play many physiological roles in healthy tissues – AM-411 targets only inflamed tissues - Less likelihood of resistance: Blocking production of an NF-κB component by degrading mRNA to cause less resistance than inhibition of NF-κB Discover more as Altamira hopes to transform treatment paradigms for partients battling RA: https://bit.ly/3JjIBix #Science #RNADelivery #siRNA #mRNA #RNATherapeutics

Can #ketamine and its metabolites, such as HNK, be used beyond depression as therapeutics? We explored that in a now published manuscript, demonstrating that HNK can reverse synaptic and behavioural deficits in mouse models of #Alzheimers… check it out! https://lnkd.in/eEm9cHAx

Argenica Therapeutics is developing a novel peptide drug, ARG-007, that has shown great results in preclinical models of ischaemic stroke and is now being tested in a Phase 2 trial in ischaemic stroke patients in hospitals across Australia. The way the drug was discovered and the mechanism by which it works to reduce brain injury gives a solid scientific basis for progressing this drug through clinical trials. Joining us to talk more about the discovery of ARG-007 and it’s unique mechanism of action is Argenica’s Chief Scientific Officer, and inventor of ARG-007, Prof Bruno Meloni. Joining Bruno is Argenica’s CEO Dr Liz Dallimore Spotify: https://spoti.fi/3NrDvCd Stewart Walters Holly Walters Riley Maring Dianne Angus Liddy McCall Meghan Thomas Emma Waldon Adam Edwards MarketOpen #ArgenicaTherapeutics #AGN #ARG007 #BrainInjury #Stroke #Science #ClinicalTrials